1
|
Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, Adamia S, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi NC. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J 2016; 6:e380. [PMID: 26771806 PMCID: PMC4742623 DOI: 10.1038/bcj.2015.106] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Accepted: 11/16/2015] [Indexed: 12/19/2022] Open
Abstract
Deregulated microRNA (miR)/transcription factor (TF)-based networks represent a hallmark of cancer. We report here a novel c-Myc/miR-23b/Sp1 feed-forward loop with a critical role in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cell growth and survival. We have found miR-23b to be downregulated in MM and WM cells especially in the presence of components of the tumor bone marrow milieu. Promoter methylation is one mechanism of miR-23b suppression in myeloma. In gain-of-function studies using miR-23b mimics-transfected or in miR-23b-stably expressing MM and WM cell lines, we observed a significant decrease in cell proliferation and survival, along with induction of caspase-3/7 activity over time, thus supporting a tumor suppressor role for miR-23b. At the molecular level, miR-23b targeted Sp1 3'UTR and significantly reduced Sp1-driven nuclear factor-κB activity. Finally, c-Myc, an important oncogenic transcription factor known to stimulate MM cell proliferation, transcriptionally repressed miR-23b. Thus MYC-dependent miR-23b repression in myeloma cells may promote activation of oncogenic Sp1-mediated signaling, representing the first feed-forward loop with critical growth and survival role in myeloma.
Collapse
Affiliation(s)
- M Fulciniti
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - N Amodio
- Department of Experimental and Clinical Medicine, Magna Græcia University of Catanzaro, Salvatore Venuta Campus, Catanzaro, Italy
| | - R L Bandi
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - A Cagnetta
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - M K Samur
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - C Acharya
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - R Prabhala
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
| | - P D'Aquila
- Department of Biology, Ecology and Earth Science (DiBEST), University of Calabria, Arcavacata di Rende, Cosenza, Italy
| | - D Bellizzi
- Department of Biology, Ecology and Earth Science (DiBEST), University of Calabria, Arcavacata di Rende, Cosenza, Italy
| | - G Passarino
- Department of Biology, Ecology and Earth Science (DiBEST), University of Calabria, Arcavacata di Rende, Cosenza, Italy
| | - S Adamia
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - A Neri
- Department of Medical Sciences, University of Milan, Hematology 1, IRCCS Policlinico Foundation, Milan, Italy
| | - Z R Hunter
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S P Treon
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - K C Anderson
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - P Tassone
- Department of Experimental and Clinical Medicine, Magna Græcia University of Catanzaro, Salvatore Venuta Campus, Catanzaro, Italy
| | - N C Munshi
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
2
|
Prabhala RH, Fulciniti M, Pelluru D, Rashid N, Nigroiu A, Nanjappa P, Pai C, Lee S, Prabhala NS, Bandi RL, Smith R, Lazo-Kallanian SB, Valet S, Raje N, Gold JS, Richardson PG, Daley JF, Anderson KC, Ettenberg SA, Di Padova F, Munshi NC. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia 2015; 30:379-89. [PMID: 26293646 PMCID: PMC4740263 DOI: 10.1038/leu.2015.228] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Revised: 06/23/2015] [Accepted: 07/09/2015] [Indexed: 12/14/2022]
Abstract
We have previously demonstrated that interleukin-17A (IL-17) producing Th17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM cell growth via the expression of IL-17 receptor. In this study, we evaluated anti-human IL-17A human monoclonal antibody (mAb), AIN457 in MM. We observe significant inhibition of MM cell growth by AIN457 both in the presence and absence of BM stromal cells (BMSC). While IL-17A induces IL-6 production, AIN457 significantly down-regulated IL-6 production and MM cell-adhesion in MM-BMSC co-culture. AIN-457 also significantly inhibited osteoclast cell–differentiation. More importantly, in the SCIDhu model of human myeloma administration of AIN-457 weekly for 4 weeks after the first detection of tumor in mice led to a significant inhibition of tumor growth and reduced bone damage compared to isotype control mice. To understand the mechanism of action of anti-IL-17A mAb, we report here, that MM cells express IL-17A. We also observed that IL-17A knock-down inhibited MM cell growth and their ability to induce IL-6 production in co-cultures with BMSC. These pre-clinical observations suggest efficacy of AIN 457 in myeloma and provide the rationale for its clinical evaluation for anti-myeloma effects and for improvement of bone disease.
Collapse
Affiliation(s)
- R H Prabhala
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.,Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - M Fulciniti
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - D Pelluru
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - N Rashid
- Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - A Nigroiu
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
| | - P Nanjappa
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - C Pai
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
| | - S Lee
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
| | - N S Prabhala
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
| | - R L Bandi
- Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - R Smith
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S B Lazo-Kallanian
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S Valet
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - N Raje
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - J S Gold
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.,Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - P G Richardson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - J F Daley
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - K C Anderson
- Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S A Ettenberg
- Novartis Institute for Biomedical Research, Cambridge, MA, USA
| | - F Di Padova
- Novartis Institute for Biomedical Research, Basel, Switzerland
| | - N C Munshi
- Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.,Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| |
Collapse
|